LISATA THERAPEUTICS, INC. Cost of Revenue
LISATA THERAPEUTICS, INC. (LSTA) reported Cost of Revenue of $8.04 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-15.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2017-05-15
- LISATA THERAPEUTICS, INC. cost of revenue for the quarter ending 2017-03-31 was $8.04M, a 29.13% increase year-over-year.
- LISATA THERAPEUTICS, INC. cost of revenue for the quarter ending 2016-12-31 was $9.25M, a 49.53% increase year-over-year.
- LISATA THERAPEUTICS, INC. cost of revenue for the quarter ending 2016-09-30 was $8.61M, a 79.08% increase year-over-year.
- LISATA THERAPEUTICS, INC. cost of revenue for the quarter ending 2016-06-30 was $7.05M, a 21.60% increase year-over-year.
- LISATA THERAPEUTICS, INC. cost of revenue for fiscal 2016 was $31.14M, a 54.45% increase from fiscal 2015.
- LISATA THERAPEUTICS, INC. cost of revenue for fiscal 2015 was $20.16M, a 28.58% increase from fiscal 2014.
- LISATA THERAPEUTICS, INC. cost of revenue for fiscal 2014 was $15.68M, a 21.10% increase from fiscal 2013.
- LISATA THERAPEUTICS, INC. cost of revenue for fiscal 2013 was $12.95M, a 8.35% increase from fiscal 2012.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-03-31 | $8.04M 10-Q · filed 2017-05-15 | $17.29M derived: sum of 2 quarters · filed 2017-05-15 | $25.90M derived: sum of 3 quarters · filed 2017-05-15 | $32.95M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2016-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | $17.86M derived: sum of 2 quarters · filed 2017-03-17 | $24.91M derived: sum of 3 quarters · filed 2017-03-17 | $31.14M 10-K · filed 2017-03-17 | ||||
| 2016-09-30 | $8.61M 10-Q · filed 2016-11-07 | $15.66M derived: sum of 2 quarters · filed 2016-11-07 | $21.89M 10-Q · filed 2016-11-07 | $28.07M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2016-06-30 | $7.05M 10-Q · filed 2016-08-09 | $13.28M 10-Q · filed 2016-08-09 | $19.46M derived: sum of 3 quarters · filed 2017-05-15 | $24.27M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2016-03-31 | $6.23M 10-Q · filed 2017-05-15 | $12.41M derived: sum of 2 quarters · filed 2017-05-15 | $17.22M derived: sum of 3 quarters · filed 2017-05-15 | $23.02M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | $10.99M derived: sum of 2 quarters · filed 2017-03-17 | $16.79M derived: sum of 3 quarters · filed 2017-03-17 | $20.16M 10-K · filed 2017-03-17 | ||||
| 2015-09-30 | $4.81M 10-Q · filed 2016-11-07 | $10.61M derived: sum of 2 quarters · filed 2016-11-07 | $13.98M 10-Q · filed 2016-11-07 | $18.14M derived: sum of 4 quarters · filed 2016-11-07 | ||||
| 2015-06-30 | $5.80M 10-Q · filed 2016-08-09 | $9.17M 10-Q · filed 2016-08-09 | $13.33M derived: sum of 3 quarters · filed 2016-08-09 | $17.34M derived: sum of 4 quarters · filed 2016-08-09 | ||||
| 2015-03-31 | $3.37M 10-Q · filed 2016-05-05 | $7.53M derived: sum of 2 quarters · filed 2016-05-05 | $11.54M derived: sum of 3 quarters · filed 2016-05-05 | $15.22M derived: sum of 4 quarters · filed 2016-05-05 | ||||
| 2014-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $8.18M derived: sum of 2 quarters · filed 2016-03-15 | $11.85M derived: sum of 3 quarters · filed 2016-03-15 | $15.68M 10-K · filed 2016-03-15 | ||||
| 2014-09-30 | $4.01M 10-Q · filed 2015-11-05 | $7.69M derived: sum of 2 quarters · filed 2015-11-05 | $11.52M 10-Q · filed 2015-11-05 | $14.86M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $3.68M 10-Q · filed 2015-08-06 | $7.50M 10-Q · filed 2015-08-06 | $10.85M derived: sum of 3 quarters · filed 2016-03-15 | $13.82M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $3.83M 10-Q · filed 2015-05-06 | $7.17M derived: sum of 2 quarters · filed 2016-03-15 | $10.15M derived: sum of 3 quarters · filed 2016-03-15 | $14.38M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $6.32M derived: sum of 2 quarters · filed 2016-03-15 | $10.56M derived: sum of 3 quarters · filed 2016-03-15 | $12.95M 10-K · filed 2016-03-15 | ||||
| 2013-09-30 | $2.98M 10-Q · filed 2014-10-30 | $7.21M derived: sum of 2 quarters · filed 2014-10-30 | $9.60M 10-Q · filed 2014-10-30 | $12.11M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | $4.24M 10-Q · filed 2014-08-07 | $6.63M 10-Q · filed 2014-08-07 | $9.14M derived: sum of 3 quarters · filed 2015-03-02 | $12.88M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | $2.39M 10-Q · filed 2014-05-08 | $4.90M derived: sum of 2 quarters · filed 2015-03-02 | $8.65M derived: sum of 3 quarters · filed 2015-03-02 | $11.39M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $6.26M derived: sum of 2 quarters · filed 2015-03-02 | $8.99M derived: sum of 3 quarters · filed 2015-03-02 | $11.95M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $3.75M 10-Q · filed 2013-11-07 | $6.48M derived: sum of 2 quarters · filed 2013-11-07 | $9.44M 10-Q · filed 2013-11-07 | $12.75M derived: sum of 4 quarters · filed 2013-11-07 | ||||
| 2012-06-30 | $2.74M 10-Q · filed 2013-08-08 | $5.69M 10-Q · filed 2013-08-08 | $9.00M derived: sum of 3 quarters · filed 2013-08-08 | $10.89M derived: sum of 4 quarters · filed 2013-08-08 | ||||
| 2012-03-31 | $2.96M 10-Q · filed 2013-05-09 | $16.32M 10-Q · filed 2012-05-11 | $6.27M derived: sum of 2 quarters · filed 2013-05-09 | $8.16M derived: sum of 3 quarters · filed 2013-05-09 | $9.95M derived: sum of 4 quarters · filed 2013-05-09 | |||
| 2011-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $5.20M derived: sum of 2 quarters · filed 2013-03-11 | $6.99M derived: sum of 3 quarters · filed 2013-03-11 | $8.65M 10-K · filed 2013-03-11 | $55.97M 10-K · filed 2012-03-20 | |||
| 2011-09-30 | $1.89M 10-Q · filed 2012-11-13 | $13.84M 10-Q · filed 2011-11-10 | $3.68M derived: sum of 2 quarters · filed 2012-11-13 | $5.34M 10-Q · filed 2012-11-13 | $41.64M 10-Q · filed 2011-11-10 | -$17.06M derived: sum of 4 quarters · filed 2012-11-13 | ||
| 2011-06-30 | $1.79M 10-Q · filed 2012-08-14 | $13.52M 10-Q · filed 2011-08-12 | $3.46M 10-Q · filed 2012-08-14 | $27.81M 10-Q · filed 2011-08-12 | -$18.95M derived: sum of 3 quarters · filed 2012-08-15 | -$7.72M derived: sum of 4 quarters · filed 2012-08-15 | ||
| 2011-03-31 | $14.28M 10-Q · filed 2012-05-11 | -$20.74M derived: sum of 2 quarters · filed 2012-08-15 | -$9.51M derived: sum of 3 quarters · filed 2012-08-15 | $3.41M derived: sum of 4 quarters · filed 2012-08-15 | ||||
| 2010-12-31 | -$35.02M derived: 8-K 12 month − 10-Q 9 month · filed 2012-08-15 | -$23.78M derived: sum of 2 quarters · filed 2012-08-15 | -$10.87M derived: sum of 3 quarters · filed 2012-08-15 | $0.00 8-K · filed 2012-08-15 | $49.67M 10-K · filed 2012-03-20 | |||
| 2010-09-30 | $11.23M 10-Q · filed 2011-11-10 | $24.14M derived: sum of 2 quarters · filed 2011-11-10 | $35.02M 10-Q · filed 2011-11-10 | |||||
| 2010-06-30 | $12.91M 10-Q · filed 2011-08-12 | $23.76M 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |